drugset / Trial / NCT03096418
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Phase 4
Recruiting
50 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Timeline
- Start
- 2017-03-13
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Other |